Acetylisoselenocyanat | 59766-65-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Acetylisoselenocyanat
• CAS: 59766-65-3
• 化学式: C₃H₃NOSe
• 分子量: 148.023
• InChiKey: DGGPBYFOPSPKDE-UHFFFAOYSA-N

物化性质

• 沸点：
  155.3±23.0 °C(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.39
• 重原子数：
  6
• 可旋转键数：
  0
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  29.4
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-氨基吡啶 、 Acetylisoselenocyanat 以 丙酮 为溶剂， 反应 8.0h， 以0.13 g的产率得到4-methyl-2H-pyrido[1,2-a][1,3,5]triazine-2-selenone
  参考文献：
  名称：

  从酰基异戊烯异氰酸酯和吡啶-2-胺一锅法合成2 H-吡啶并[1,2- a] [1,3,5]三嗪-2-硒酮

  摘要：

  摘要由酰基氯和硒氰酸钾制得的酰基异异氰酸酯被吡啶-2-胺截留，以中等至良好的产率得到4-取代的吡啶并[1,2- a ] [1,3,5]三嗪-2-硒酮。 图形概要

  DOI：

  10.1007/s00706-016-1834-3
• 作为产物：
  描述：

  potassium selenocyanate 、 乙酰氯 以 丙酮 为溶剂， 反应 0.17h， 生成 Acetylisoselenocyanat
  参考文献：
  名称：

  从酰基异戊烯异氰酸酯和吡啶-2-胺一锅法合成2 H-吡啶并[1,2- a] [1,3,5]三嗪-2-硒酮

  摘要：

  摘要由酰基氯和硒氰酸钾制得的酰基异异氰酸酯被吡啶-2-胺截留，以中等至良好的产率得到4-取代的吡啶并[1,2- a ] [1,3,5]三嗪-2-硒酮。 图形概要

  DOI：

  10.1007/s00706-016-1834-3

文献信息

• The Preparation of Acylselenourea and Selenocarbamate Using Isoselenocyanate
  作者：Mamoru Koketsu、Yusuke Yamamura、Hiroshi Aoki、Hideharu Ishihara

  DOI：10.1080/10426500600862894

  日期：2006.12.1

  Acyl isoselenocyanates were prepared by a reaction of acyl chloride with KSeCN. The acyl isoselenocyanates formed in situ were ready for further reaction without concentration. N-Acyl selenoureas were obtained by a reaction of acyl isoselenocyanates with amines. The reaction of acyl isoselenocyanates with nucleophiles gave the corresponding selenocarbamate. All the compounds were well characterized

  酰基异硒氰酸酯是通过酰氯与 KSeCN 反应制备的。原位形成的酰基异硒氰酸酯无需浓缩即可用于进一步反应。N-酰基硒脲是通过酰基异硒氰酸酯与胺的反应获得的。酰基异硒氰酸酯与亲核试剂反应得到相应的硒代氨基甲酸酯。通过使用光谱数据，如 13C 和 77Se NMR 和 X 射线衍射，对所有化合物进行了很好的表征。
• Ferrocene incorporated selenoureas as anticancer agents
  作者：Raja Azadar Hussain、Amin Badshah、John M. Pezzuto、Nadeem Ahmed、Tamara P. Kondratyuk、Eun-Jung Park

  DOI：10.1016/j.jphotobiol.2015.04.024

  日期：2015.7

  For a compound to be a best chemopreventive agent it should be a descent DNA binder and at the same time should be active against any of the three stages of carcinogenesis i.e. cancer initiation, cancer propagation and tumor growth. Most of the problems associated with chemotherapy can be overcome if the chemopreventive agent is active against all the three stages of cancer development. Cancer may be initiated by higher concentration of free radicals, inflammating agents and phase I enzymes (Cytochrome P450) in the body. Cancer propagation can be very efficiently controlled by inducing the phase II enzymes (glutathione S-transferases (GSTs), UDP-glucuronosyl transferases, and quinone reductases) in the body and cancer termination depends on the killing of the faulty cells i.e. cytotoxic actions. This article reports comprehensively the comparative DNA binding studies (with, cyclic voltammetry, UV-vis spectroscopy and viscometry), antioxidant activities (DPPH scavenging), anti-inflammatory activities (nitrite inhibition), phase I enzyme inhibition activities (aromatase inhibition), phase II enzyme induction studies (quinone reductase induction) and cytotoxic studies against neuroblastoma (MYCN2 and SK-N-SH), liver cancer (Hepa 1c1c7) and breast cancer (MCF-7) of seventeen ferrocene incorporated selenoureas. (C) 2015 Elsevier B.V. All rights reserved.
• Synthesis, characterization and biological applications of selenoureas having ferrocene and substituted benzoyl functionalities
  作者：Raja Azadar Hussain、Amin Badshah、Nadeem Ahmed、John M. Pezzuto、Tammara P. Kondratyuk、Eun-Jung Park、Iqtadar Hussain

  DOI：10.1016/j.poly.2019.05.027

  日期：2019.9

  In this article we have comprehensively reported the synthesis, complete chemical characterization (FTIR, multinuclear NMR, single crystal XRD, CHNS, AAS) and biological applications of seventeen ferrocene incorporated selenoureas. Biological applications include comparative DNA binding studies (with, cyclic voltammetry), antioxidant activities (DPPH (2,2-diphenyl-1-picrylhydrazyl) scavenging), anti-inflammatory activities (nitrite inhibition), phase I enzyme inhibition activities (aromatase inhibition), phase II enzyme induction studies (quinone reductase induction) and cytotoxic studies against neuroblastoma (MYCN2 and SK-N-SH), liver cancer (Hepa 1c1c7) breast cancer (MCF-7) and human cervical carcinoma HeLa cells (ATCC (R) CCL-2). All the compounds showed decent structure dependent biological applications. (C) 2019 Elsevier Ltd. All rights reserved.